

CURRICULUM VITAE



I. PERSONAL DATA

- Name: Saeid
- Surname: Bouzari
- Date of Birth: 1959
- Place of Birth: Tehran
- Nationality: Iranian
- Marital Status: Married (two children)
- Work address: Molecular Biology Unit, Pasteur Institute of Iran, Pasteur Ave, Tehran 13164, Iran.
- Phone: (9821) 66953311-20 (EXT-2223)
- Fax: (9821) 66492619
- E-Mail: saeidbouzari@yahoo.com

II. Academic degrees

Year	Degree	University	Place, country	Subject
1983	B. Sc.	Shivaji	Kolhapur, India	Microbiology
1985	M. Sc.	Indore	Indore, India	Life Sciences
1991	Ph. D.	Delhi	Delhi, India	Medical Microbiology

III. Professional Background:

- Since July 1991-	Researcher	Molecular Biology Unit, Pasteur Institute of Iran
--------------------	-------------------	--

Since 2008	Professor	
-------------------	------------------	--

Teaching experience:

1995-1996 M. Sc. In Microbiology Pasteur Institute of Iran
1996-Present M. Sc. Course in Genetic Engineering Free University, Tehran and Pasteur Institute of Iran
1998-present M.Sc. in Microbiology
1998-Present Ph. D. course in Molecular Biology Pasteur Institute of Iran

Workshops

2-7 March 1994 **Basic techniques in Genetic Pasteur Institute of Iran**

Engineering

9-14 March 1994

March 2009 **National workshop on Laboratory diagnosis of *Escherichia coli*, *Shigella* and *Salmonella***

July 2010 **National workshop on Laboratory diagnosis of *Escherichia coli*, *Shigella* and *Salmonella* and quality controls in Microbiology Laboratory**

Supervision of theses

M. Sc. Student 25

Ph. D. 8

V. Administration:

1999- 2013 Educational advisor to Ph. D. students Pasteur Institute of Iran

2002-2003 head of Education Department (PII)

1998-2013 Member of Educational council (PII)

2008-present Member of Research council (PII)

2007- Present Editorial board of Iranian Biomedical Journal (IBJ)

2008-present Editorial board of Iranian Journal of Microbiology (IJM)

2007- Present Member of Board of Medical Biotechnology and molecular medicine
Ministry of health

2009- Present Head of the Molecular Biology Unit, Pasteur Institute of Iran (PII)

2009-present Head of national *Escherichia coli* Reference laboratory (NERL) (PII)

Sep-2011-Sep2013 Deputy Director for research (PII)

May2012-present Director of Microbiology Department

May2013- Sep-2013 Acting Director of Pasteur institute of Iran (PII)

2012- Present Head of Microbiology Department

2014-Present Deputy Director of Research Pasteur institute of Iran

VI- Previous periods of study and research abroad:

Nov. 1996- July 1997

Pasteur Institute of Paris (PIP)- France

Research (Post-doc)

Pasteur Institute of Paris (PIP)

Dr. Agnes Labigne (PIP)

Sep 2001- Aug 2002

Medical Mikrobiologie Giessen-Germany

Research (Post-doc)

Humboldt- Fellowship Award (Germany)

Professor Trinad- Chakraborty

Sep 2003- July 2004

University of British Columbia(UBC) Vancouver-Canada

Research Post-doctoral

Fellowship (UBC)

Dr. B.A. Vallance

Publication list:

1. **Bouzari, S.,** Varghese, A. (1990): Cytolethal distending toxin (CLDT), production by enteropathogenic *Escherichia coli* (EPEC). **FEMS Microbiol Letts 71,193-198.**
2. Vatsala, B.R., **Bouzari, S.,** Varghese, A. (1990): Congo red binding ability among enteroinvasive and other *Escherichia coli* strains. **Med Sci Res 18, 971.**
3. **Bouzari, S.,** Vatsala, B.R., Varghese, A. (1992): *In vitro* adherence property of cytolethal distending toxin (CLDT) producing EPEC strains and effect of the toxin on rabbit intestine. **Microb pathog 12, 153-157.**
4. Jafari, A., **Bouzari, S.,** Farhoudi-Moghaddam, A.A. (1992): Drug resistance in diarrhogenic *Escherichia coli* (ETEC, EPEC). **Iran J Med Sci 17, 51-55.**
5. **Bouzari, S.,** Vatsala, B.R., Varghese, A. (1994): Characterisation of vero-toxin producing EPEC strains: effect of toxin on rabbit intestine. **Med J I Rep Iran 8, 47-**
6. **Bouzari, S.,** Jafari, A., Farhoudi-Moghaddam, A.A., Shokouhi, F., Parsi, M. (1994): Adherence of non-enteropathogenic *Escherichia coli* to HeLa cells. **J Med Microbiol 40, 95-97.**
7. Jafari, A, **Bouzari, S,** Farhoudi-Moghaddam, A.A., Parsi, M., Shokouhi, F. (1994): *In vitro* adherence and invasion of *Salmonella enterica* serotype Havana. **Microb Pathog 16, 65-70.**
8. Aslani, M.M., Badami, N., Mahmoodi, M., and **Bouzari, S.** (1998): Vero-toxin producing *Escherichia coli* (VTEC) infection in randomly selected population of Ilam province (Iran). **Scand J Infect Dis 30, 473-476.**
9. **Bouzari, S.,** Rechinsky, V.O. (1998): Cloning and Expression of *Thermus aquaticus* DNA polymerase gene, using a thermo-inducible expression vector. **Iran Biomed J 2, 79-83.**
10. Oloomi, M., **Bouzari, S.,** Rechinsky, V.O. (1998): PCR-mediated expression of the human GM-CSF gene in *E.coli*. **Iran Biomed J 1998, 2(1): 21-25.**
11. Oloomi, M., **Bouzari, S.,** Rechinsky, V.O. (1999): Purification and characterization of the cloned human GM-CSF gene expressed in *E.coli*. **Med J I R I 12, 353-357.**
12. Aslani, M.M., Badami, N., **Bouzari, S.** (1999): Adherence patterns of verotoxigenic *Escherichia coli* (VTEC) non-O157 strains isolated from faecal samples in Iran.

Iran Biomed J 3, 71-75.

13. Bouzari, S., Oloomi, M., Salmanian, A.H., Jafari, A. (1999): Construction and expression of a fused gene for B subunit of heat-labile and a truncated form of heatstable enterotoxins in *Escherichia coli*. **Iran Biomed J 3, 83-86.**

14. Bouzari, S., Jafari, M.N., Shoukahi, F., Parsi, M., Jafari, A. (2000): Virulencerelated DNA sequences and adherence patterns in strains of enteropathogenic *Escherichia coli* (EPEC) strains. **FEMS Microbiol Letts 185, 89-93.**

15. Bouzari, S., Jafari, A., Azizi, A., Oloomi, M., Nataro, J.P. (2001): Characterization of enteroaggregative *Escherichia coli* (EAEC) isolates from Iranian children. **Am J Trop Med Hug. 65 (1): 13-14. :**

16 Le Bouguenec C,Laliouli L,du Merle L,Jouve M,Courcoux P, Bouzari S, Selvarangan R, Nowicki BJ, Germani Y, Adremont A,Gounon P, Garcia MI (2001). Characterization of AfaE adhesins produced by extraintestinal and intestinal human *Escherichia coli* isolates: PCR assays for detection of Afa adhesins that do or do not recognize Dr blood group antigens.

J Clin Microbiol. ;39(5):1738-45.

17. Jafari, A., Katouli M., Shokouhi, F, and **Bouzari S. (2001).** Detection and characterization of Verotoxin-producing strains among non-sorbitol fermenting *Escherichia coli*. **East. Med. Health J. 7, (4/5):121-127.**

18. Shahrokhi, N., Jafari, A., Bakayev, V., Schirnbeck, R., Reinan, J., **Bouzari S. (2002)** Construction of Hybrid gene of Hepatitis B surface Antigen carrying Heat-stable Enterotoxin of *Escherichia coli* and it's Expression in mammalian cell line. **Iran Biomed J 6(2,3):47-53**

19. Aslani, M.M., Bouzari, S. (2003) An epidemiological study on Verotoxin producing *Escherichia coli* (VTEC) infection among population of Northern region of Iran.

European Journal of Epidemiology 18:345-349.

20. Mana Oloomi and Saeid Bouzari (2004). Improvement of h GM-CSF expression using a fusion system by directing protein to the periplasmic space. **Medical Journal of IRI ;18/2 : 141-146**

21. Bouzari, S. A.jafari., A.Zarepoor (2005). Distribution of virulence related genes among enteroaggregative *Escherichia coli* isolates: using Multiplex PCR and hybridization. **Infection Genetics and Evolution.5 (1):79-83.**

22 .Bouzari, S Oloomi,.M. E.Oswald .(2005).Detection of cytolethal distending toxin

locus *cdtB* among diarrheagenic *Escherichia coli* human isolates from Iran. **Research in Microbiology. 156(2):137-144.**

23. Habibi Roudkenar, M., **Bouzari S.**, Oloomi M., Jafari A., Shahrokhi N., Shokrgozar MA. (2005). Expression of a chimeric protein containing the catalytic domain of Shigatoxin

and human Granulocyte Macrophage Colony – Stimulating Factor (h GM-CSF) in *Escherichia coli* and its recognition by reciprocal antibodies. **Iran Biomed J 9(4):143-148.**

24. M Oloomi and **Bouzari, S.** (2006) Comparison of PCR systems for Detection of different *cdt* genes in *Escherichia coli* isolates. **Lett Appl Microbiol 42(5): 445-451.**

25. Nader Shahrokhi, **Saeid Bouzari** and Anis Jafari (2006). Priming Hepatitis B Surface (HBsAg) and Core Antigen (HBcAg) Specific Immune Responses by chimeric HBcAg 'a' Determinant. **Iran Biomed J 10(2): 61-68.**

26. Mehryar Habibi Roudkenar, Anis Jafari, Mana Oloomi, and **Saeid Bouzari** (2006) Selective cytotoxicity of recombinant STXA1-GM-CSF protein in hematopoietic cancer cells. **Cell Biol Toxicol 22(3): 213-219.**

27. Mehryar Habibi Roudkenar, **Saeid Bouzari***, Yoshikazu Kuwahara, Amaneh Mohammadi Roushandeh, Mana Oloomi, Manabu Fukumoto. (2006) Recombinant Hybrid Protein, Shiga-Toxin and granulocyte macrophage colony stimulating factor, Effectively Induces Apoptosis of Colon Cancer Cells. **World J Gastroenterol 12(15): 2341-2344.**

28. Oloomi M, **Bouzari S**, Arshadi M. (2006). N-terminus leader sequence of shiga toxin(*stx1*) is essential for production of active recombinant protein in *E. coli*. **Protein Pept Lett, 13(5): 5015.**

29. **Bouzari, S.** Jafari, A., Zarepoor, M., (2007) Distribution of genes encoding different toxins and determination of resistance patterns among diarrhogenic *Escherichia coli* isolates in Iran. **East. Med. Health J. 13(2): 287-293.**

30. Habibi Roudkenar M, **Bouzari, S.** Oloomi, M, Kuwahara, Y., Mohammadi Roushandeh A, Baba T., Fukumoto, M., (2007). Assessment of GM-CSF receptors by real-time RT-PCR on cell lines expressing high and low affinity receptors and their relation to cytotoxic effect of chimeric protein (StxA1-GM-CSF). **Daru. 15(3):151-155.**

31. Habibi Roudkenar M, **Bouzari, S.**, Kuwahara, Y., Mohammadi Roushandeh A, Baba T., Oloomi, M, Fukumoto, M., (2008). Induction of apoptosis on K562 cell line and double strand breaks on Colon cancer cell line expressing high affinity receptor for

Granulocyte Macrophage –colony Stimulating Factor (GM-CSF). **Iran Biomed J ; 12(1): 1-6.**

32. Oloomi M. and **Bouzari S. (2008).** Molecular profile and genetic diversity of cytolethal distending toxin (CDT)-producing *Escherichia coli* isolates from diarrheal patients. **APMIS.** 116 (2):125-32.

33. Bergstrom KS, Guttman JA, Rumi M, Ma C, **Bouzari S**, Khan MA, Gibson DL, Vogl AW, Vallance BA **(2008).** Modulations of intestinal goblet cell function during infection by an attaching and effacing bacterial pathogen. **Infect. Immun; 76 (2): 796- 811.**

34. (Mohammed A. Khan, **Saeid Bouzari**, I Caixia Ma, Carrie M. Rosenberger, Kirk S. B. Bergstrom, Deanna L. Gibson, Theodore S. Steiner, and Bruce A. Vallance **(2008)** Flagellin-dependent and -independent inflammatory responses following infection by enteropathogenic *Escherichia coli* (EPEC) and *Citrobacter rodentium*. **Infect Immun; 76 4): 1410-1422.**

35. Oloomi M, **Bouzari S**, Ajdary S, **(2008).** Immune response of mice immunized with active recombinant Shiga Toxin and its derivatives. **Iran J Allergy Asthema Immunol; 7(2): 53-60.**

36. Aslani MM, **Bouzari S (2009).** Characterization of virulence genes of non-O157 Shiga toxin-producing *Escherichia coli* isolates from two provinces of Iran. **Jpn J Infect Dis. 62(1):16-9.**

37. **Saeid Bouzari**, Mana Oloomi, and Kayhan Azadmanesh **(2009)** Study on induction of apoptosis on HeLa and Vero cells by recombinant shiga toxin and its subunits. **Cytotechnology.** 60(1-3): 105–113.

38. Oloomi M, Bouzari S, Emami S **(2009)** A recombinant hybrid peptide composed of AAF adhesin of enteroaggregative *Escherichia coli* and Shiga toxin B subunit elicits protective immune response in mice. **Eur J Clin Microbiol Infect Dis.** 28(11):1311-6.

39. **Bouzari S***, Amir Dashti, Anis Jafari, Mana Oloomi **(2010):** Immune response against adhesins of enteroaggregative *Escherichia coli* immunized by three different vaccination strategies (DNA/DNA, Protein/Protein, and DNA/Protein) in mice. **Comp Immunol Microbiol Infect Dis.** 33(3):215-25.

40. Oloomi M, **Bouzari S**, Shariati E **(2010).** In vivo characterization of fusion protein comprising of A1 subunit of Shiga toxin and human GM-CSF: Assessment of its immunogenicity and toxicity. **Iran Biomed J. 14(4):136-41.**

41. Oloomi M, **Bouzari S (2011)** Characterization of Rabbit Polyclonal Sera against Recombinant Shiga Toxin and

its Subunits for Detection of Stx-Producing E. coli. **Iran J Allergy Asthma Immunol.** **10(1):41-6.**

42. Oloomi M, **Bouzari S (2011).** Assessment of immune response of the B subunit of Shiga toxin fused to AAF adhesin of enteroaggregative *Escherichia coli*. **Microb Pathog.** 50(3-4):155-8.

43. Oloomi M, **Bouzari S. (2011)** Characterization of rabbit polyclonal sera against recombinant Shiga toxin and its subunits for detection of Stx-producing E. coli. **Iran J Allergy Asthma Immunol.** Mar;10(1):41-6.

44. Bouzari S, Aslani MM, Oloomi M, Jafari A, Dashti A. **(2011)** Comparison of multiplex PCR with serogrouping and PCR-RFLP of fliC gene for the detection of enteropathogenic *Escherichia coli* (EPEC). **Braz J Infect Dis.** Jul-Aug;15(4):365-9.

45. Shahrokhi N, **Bouzari S,** Jafari A. **(2011)** Comparison of virulence markers and antibiotic resistance in enterotoxigenic *Escherichia coli* isolated ten years apart in Tehran. **J Infect Dev Ctries.** Apr 26;5(4):248-54.

46. Chinikar S, Shah-Hosseini N, **Bouzari S,** Jalali T, Shokrgozar MA, Mostafavi E. **(2012)** New circulating genomic variant of Crimean-Congo hemorrhagic fever virus in Iran. **Arch Virol.** Dec 28. [Epub ahead of print]

47. Jahanian-Najafabadi A, **Bouzari S,** Oloomi M, Roudkenar MH, Shokrgozar MA. **(2012)** Assessment of selective toxicity of insect cell expressed recombinant A1-GMCSF protein toward GMCSF receptor bearing tumor cells. **Res Pharm Sci.** Jul;7(3):133-40.

48. Jafari A, Aslani MM, **Bouzari S. (2012)** *Escherichia coli*: a brief review of diarrheagenic pathotypes and their role in diarrheal diseases in Iran. **Iran J Microbiol.** Sep;4(3):102-17.

49. Habibi Anbouhi M, Feiz Barazandeh A, **Bouzari S,** Abolhassani M, Khanahmad H, Golkar M, Aghasadeghi MR, Behdani M, Jahanian-Najafabadi A, Shokrgozar MA. **(2012)** Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigen. **Iran Biomed J.**;16(3):121-6..

50. Asadi KM, Oloomi M, Habibi M, **Bouzari S. (2012)**

Cloning of fimH and fliC and expression of the fusion protein FimH/FliC from Uropathogenic Escherichia coli (UPEC) isolated in Iran.

Iran J Microbiol. Jun;4(2):55-62.

51. Oloomi M, **Bouzari S**, Mohagheghi MA, Khodayaran-Tehrani H (2012)
Molecular Markers in Peripheral Blood of Iranian Women with Breast Cancer. **Cancer Microenviron.** Jul 25. [Epub ahead of print]

52. Noroozian Z, Oloomi M, **Bouzari S.** (2012)
Analyzing of expression of novel polypeptide complexes consisting of Shiga toxin B subunit and Adherence Fimbriae of Escherichia coli based on in silico modeling. **J Mol Model.** Sep; 18(9):4131-9.

53. Jahanian-Najafabadi A, **Bouzari S**, Oloomi M, Roudkenar MH, Mayr LM(2012)
Attempts to express the A1-GMCSF immunotoxin in the baculovirus expression vector system.

.Biosci Biotechnol Biochem.; 76(4):749-54. Epub 2012 Apr 7.

54.Asadi Karam MR, Oloomi M, Mahdavi M, Habibi M, **Bouzari S.** (2013)
Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.

Vaccine. Feb 6; 31(8):1210-6.

55. Karam MR, Oloomi M, Mahdavi M, Habibi M, **Bouzari S.** (2013)
Assessment of immune responses of the flagellin (FliC) fused to FimH adhesin of Uropathogenic Escherichia coli.

Mol Immunol. May; 54(1):32-9.

56. Moazzezy N, Oloomi M, **Bouzari S.** (2014)

Effect of shiga toxin and its subunits on cytokine induction in different cell lines. **Int J Mol Cell Med.**;3(2):108-17.

57. Jafari A, Aslani MM, **Bouzari S.** (2013)

Enteroaggregative Escherichia coli, a heterogenous, underestimated and under-diagnosed E. coli pathotype in Iran. **Gastroenterol Hepatol Bed Bench;**6(2):71-9. Review.

58. Moazzezy N, Farahany TZ, Oloomi M, **Bouzari S.**

Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer.

Asian Pac J Cancer Prev.;15(4):1685-8.

59. Savar NS, Bouzari S. (2014)

In silico study of ligand binding site of toll-like receptor.

Adv Biomed Res. 24;3:41. doi: 10.4103/2277-9175.125730. eCollection 2014.

60. Savar NS, Jahanian-Najafabadi A, Mahdavi M, Shokrgozar MA, Jafari A, Bouzari S. (2014) In silico and in vivo studies of truncated forms of flagellin (FliC) of enteroaggregative Escherichia coli fused to FimH from uropathogenic Escherichia coli as a vaccine candidate against urinary tract infections. **J Biotechnol.** 10;175:31-7. doi: 10.1016/j.jbiotec.2014.01.037. Epub 2014 Feb 12.

61. Jafari A, Shafaei E, Oloomi M, Aghasadeghi MR, Bouzari S. (2013)

Genotypic and Phenotypic Comparison of Enteroaggregative Escherichia coli Isolates from HIV-Positive and Non-HIV Diarrheal Samples.

Curr HIV Res.;11(8):635-41.

62. Aflakiyan S, Sadeghi HM, Shokrgozar M, Rabbani M, Bouzari S, Jahanian-Najafabadi A. (2013) Expression of the recombinant plasminogen activator (reteplase) by a non-lytic insect cell expression system.

Res Pharm Sci.;8(1):9-15.

63. Montazeri H, Bouzari S, Azadmanesh K, Ostad SN, Ghahremani MH(2013) P53 but not cyclin E acts in a negative regulatory loop to control HER-2 expression in MCF-7 breast carcinoma cell line.

Acta Med Iran. 9;51(8):513-9.

64. Anbouhi MH, Abolhassani M, **Bouzari S**, Khanahmad H, Aghasadeghi MR, Madadkar-Sobhani A, Amanzadeh A, Behdani M, Shokrgozar MA. (2012)

Immunological evaluation of predicted linear B-cell epitopes of human CD20 antigen.
Biotechnol Appl Biochem.;59(3):186-92. doi: 10.1002/bab.1012. Epub 2012 Mar 27.

65. Oloomi M, Yardehnavi N, **Bouzari S**, Moazzezy N.(2013)

Non-coding CK19 RNA in peripheral blood and tissue of breast cancer patients.

Acta Med Iran. 16;51(2):75-86.

66. Molecular Detection of Genomic Islands Associated With Class 1 and 2 Integron in Haemophilus influenzae Isolated in Iran.

Boroumand M, Irani S, Siadat SD, **Bouzari S**. Jundishapur J Microbiol. 2015 Apr 18;8(4):e17249. doi: 10.5812/jjm.8(4)2015.17249. eCollection 2015 Apr.

67. Prokaryotic High-Level Expression System in Producing Adhesin Recombinant Protein E of Nontypeable Haemophilus influenzae.

Tavakoli M, **Bouzari S**, Siadat SD, Najar Peerayeh S, Jafari A.

Jundishapur J Microbiol. 2015 Apr 18;8(4):e16377. doi: 10.5812/jjm.8(4)2015.16377. eCollection 2015 Apr.

68. Intranasal immunization with fusion protein MrpH-FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.

Habibi M, Asadi Karam MR, Shokrgozar MA, Oloomi M, Jafari A, **Bouzari S**. Mol Immunol. 2015 Apr;64(2):285-94. doi: 10.1016/j.molimm.2014.12.008. Epub 2015 Jan 4.

69. Evaluation of the effect of MPL and delivery route on immunogenicity and protectivity of different formulations of FimH and MrpH from uropathogenic

Escherichia coli and Proteus mirabilis in a UTI mouse model. Habibi M, Asadi Karam MR, **Bouzari S.**

Int Immunopharmacol. **2015 May** 29;28(1):70-78. doi: 10.1016/j.intimp.2015.05.027. [Epub ahead of print]

70. Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen.

Golshani M, Rafati S, Siadat SD, Nejati-Moheimani M, Shahcheraghi F, Arsang A, **Bouzari S.** MolImm. 2015 Aug;66(2):384-91. doi: 10.1016/j.molimm.2015.04.015. Epub 2015 May 18.

71. Molecular detection of genes related to biofilm formation in multidrug-resistant Acinetobacter baumannii isolated from clinical settings.

Badmasti F, Siadat SD, **Bouzari S,** Ajdary S, Shahcheraghi F.

J Med Microbiol. 2015 May;64 (Pt 5):538-43. doi: 10.1099/jmm.0.000058. Epub 2015 Mar

72. Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice.

Golshani M, Rafati S, Dashti A, Gholami E, Siadat SD, Oloomi M, Jafari A, **Bouzari S.** Mol Immunol. 2015 Jun;65(2):287-92. doi: 10.1016/j.molimm.2015.01.009. Epub 2015 Feb 24.

73- Genotypic Characterization of Virulence Factors in Escherichia coli Isolated from Patients with Acute Cystitis, Pyelonephritis and Asymptomatic Bacteriuria. Tabasi M, Karam MR, Habibi M, Mostafavi E, **Bouzari S.** **J Clin Diagn Res.** **2016 Dec**;10(12):DC01-DC07. doi: 10.7860/JCDR/2016/21379.9009..

74- Evaluation of the immunogenic property of NT H. influenzae protein D with Neisseria meningitidis OMV in BALB/c.

Behrouzi A, **Bouzari S,** Siadat SD, Oloomi M, Davari M, Mazaheri H.

J Infect Dev Ctries. **2016 Dec** 30;10(12):1345-1351. doi: 10.3855/jidc.7513.

75- Antiadhesive and cytoprotective effects of hydroalcoholic extract of *Apium graveolens* seeds against uropathogenic *E. coli*.

Sarshar S, Asadi Karam MR, Habibi M, **Bouzari S**, Qin X, Goycoolea FM, Hensel A. **Planta Med.** 2016 Dec;81(S 01):S1-S381. No abstract available.

76- Cytoprotective and antiadhesive effects of aqueous leaf extract from *Orthosiphon aristatus* against uropathogenic *E. coli*.

Sarshar S, Asadi Karam MR, Habibi M, **Bouzari S**, Qin X, Goycoolea FM, Brandt S, Hensel A. **Planta Med.** 2016 Dec;81(S 01):S1-S381. No abstract available.

77- Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against *Brucella* infection using *Omp2b* in BALB/c Mice.

Golshani M, Rafati S, Nejati-Moheimani M, Ghasemian M, **Bouzari S**.

Vet Microbiol. 2016 Dec 25;197:47-52. doi: 10.1016/j.vetmic.2016.10.027.

78- Use of flagellin and cholera toxin as adjuvants in intranasal vaccination of mice to enhance protective immune responses against uropathogenic *Escherichia coli* antigens. Asadi Karam MR, Habibi M, **Bouzari S**.

Biologicals. 2016 Sep;44(5):378-86. doi: 10.1016/j.biologicals.2016.06.006.

79- Genetic Diversity of Crimean Congo Hemorrhagic Fever Virus Strains from Iran. Chinikar S, **Bouzari S**, Shokrgozar MA, Mostafavi E, Jalali T, Khakifirouz S, Nowotny N, Fooks AR, Shah-Hosseini N.

J Arthropod Borne Dis. 2016 Jan 5;10(2):127-40.

80- Evaluation of Prevalence, Homology and Immunogenicity of Dispersin among Enteroaggregative Escherichia coli Isolates from Iran.

Asadi Karam MR, Rezaei AA, Siadat SD, Habibi M, **Bouzari S.**

Iran Biomed J. 2017 Jan;21(1):40-47.

81- Assessment of Cytokeratin-19 Gene Expression in Peripheral Blood of Breast Cancer Patients and Breast Cancer Cell Lines.

Keyvani S, Karimi N, Orafa Z, **Bouzari S,** Oloomi M.

Biomark Cancer. 2016 Apr 28;8:57-63. doi: 10.4137/BIC.S38229.

82- Genotype Cluster Analysis in Pathogenic Escherichia coli Isolates Producing Different CDT Types. Javadi M, Oloomi M, **Bouzari S.**

J Pathog. 2016;2016:9237127. doi: 10.1155/2016/9237127.

83- Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis. Habibi M, Asadi Karam MR, **Bouzari S.**

APMIS. 2016 Jun;124(6):444-52. doi: 10.1111/apm.12523.

84- In silico analysis of Shiga toxins (Stxs) to identify new potential vaccine targets for Shiga toxin-producing Escherichia coli.

Golshani M, Oloomi M, **Bouzari S.**

In Silico Pharmacol. 2016 Dec;5(1):2. doi: 10.1007/s40203-017-0022-4. Epub 2017 May 22.

85- Diarrheagenic *Escherichia coli* pathotypes frequency in Khuzestan province of Iran.

Darbandi A, Owlia P, **Bouzari S**, Sadari H.

Iran J Microbiol. 2016 Dec;8(6):352-358.

86- Aqueous extract from *Orthosiphon stamineus* leaves prevents bladder and kidney infection in mice.

Sarshar S, Brandt S, Asadi Karam MR, Habibi M, **Bouzari S**, Lechtenberg M, Dobrindt U, Qin X, Goycoolea FM, Hensel A.

Phytomedicine. 2017 May 15;28:1-9. doi: 10.1016/j.phymed.2017.02.009. Epub 2017 Feb 28.

87- Protein/Protein, DNA/DNA and DNA/Protein based vaccination strategies using truncated Omp2b against *Brucella* infection in BALB/c Mice.

Golshani M, Rafati S, Nejati-Moheimani M, Pourabdi S, Arsang A, **Bouzari S**.

Int J Med Microbiol. 2017 Jun;307(4-5):249-256. doi: 10.1016/j.ijmm.2017.03.004.

Epub 2017 Mar 28.

88- Genotypic Characterization of Virulence Factors in *Escherichia coli* Isolated from Patients with Acute Cystitis, Pyelonephritis and Asymptomatic Bacteriuria.

Tabasi M, Karam MR, Habibi M, Mostafavi E, **Bouzari S**.

J Clin Diagn Res. 2016 Dec;10(12):DC01-DC07. doi: 10.7860/JCDR/2016/21379.9009.

Epub 2016 Dec 1.

89- Evaluation of the immunogenic property of NT H. influenzae protein D with *Neisseria meningitidis* OMV in BALB/c.

Behrouzi A, **Bouzari S**, Siadat SD, Oloomi M, Davari M, Mazaheri H.

J Infect Dev Ctries. 2016 Dec 30;10(12):1345-1351. doi: 10.3855/jidc.7513.

90- Genotypic Characterization of Virulence Factors in *Escherichia coli* Isolated from Patients with Acute Cystitis, Pyelonephritis and Asymptomatic Bacteriuria.

Tabasi M, Karam MR, Habibi M, Mostafavi E, **Bouzari S**.

J Clin Diagn Res. 2016 Dec;10(12):DC01-DC07. doi: 10.7860/JCDR/2016/21379.9009.

Epub 2016 Dec 1.

91- In silico analysis of Shiga toxins (Stxs) to identify new potential vaccine targets for Shiga toxin-producing Escherichia coli.

Golshani M, Oloomi M, **Bouzari S.**

In Silico Pharmacol. 2016 Dec;5(1):2. doi: 10.1007/s40203-017-0022-4. Epub 2017 May 22.

92 - In Silico Signature Prediction Modeling in Cytolethal Distending Toxin-Producing Escherichia coli Strains.

Javadi M, Oloomi M, **Bouzari S.**

Genomics Inform. 2017 Jun;15(2):69-80. doi: 10.5808/GI.2017.15.2.69. Epub 2017 Jun 15.

93 - sIL-24 peptide, a human interleukin-24 isoform, induces mitochondrial-mediated apoptosis in human cancer cells.

Valiyari S, Salami M, Mahdian R, Shokrgozar MA, Oloomi M, Mohammadi Farsani A, **Bouzari S.**

Cancer Chemother Pharmacol. 2017 Sep;80(3):451-459. doi: 10.1007/s00280-017-3370-1. Epub 2017 Jun 26.

94- Recombinant truncated E protein as a new vaccine candidate against nontypeable H. influenzae: Its expression and immunogenic evaluation.

Behrouzi A, **Bouzari S,** Vaziri F, Fateh A, Afrough P, Vijeh Motlagh AD, Siadat SD.

Microb Pathog. 2017 Sep;110:431-438. doi: 10.1016/j.micpath.2017.07.025. Epub 2017 Jul 19.

95- Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.

Habibi M, Asadi Karam MR, **Bouzari S.**

Microb Pathog. 2017 Sep;110:477-483. doi: 10.1016/j.micpath.2017.07.037. Epub 2017 Jul 25.

96- Identification of different Escherichia coli pathotypes in north and north-west provinces of Iran.

Miri ST, Dashti A, Mostaan S, Kazemi F, **Bouzari S.**

Iran J Microbiol. 2017 Feb;9(1):33-37.

97 - DNA aptamer identification and characterization for E. coli O157 detection using cell based SELEX method.

Amraee M, Oloomi M, Yavari A, **Bouzari S.**

Anal Biochem. 2017 Nov 1;536:36-44. doi: 10.1016/j.ab.2017.08.005. Epub 2017 Aug 14.

98- Evaluation of immunological responses to recombinant Porin A protein (rPoA) from native strains of Neisseria meningitidis serogroups A and B using OMV as an adjuvant in BALB/c mice.

Afrough P, **Bouzari S**, Mousavi SF, Asadi Karam MR, Vaziri F, Fateh A, Behrouzi A, Malekan M, Siadat SD.

Microb Pathog. 2017 Nov;112:209-214. doi: 10.1016/j.micpath.2017.09.038. Epub 2017 Sep 20.

99 - Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.

Bameri Z, Asadi Karam MR, Habibi M, Ehsani P, **Bouzari S.**

Microb Pathog. 2018 Jan;114:99-106. doi: 10.1016/j.micpath.2017.11.015. Epub 2017 Nov 11.

100 - In silico design, cloning, expression and immunologic evaluation of ED fusion protein of NT H. influenzae.

Behrouzi A, **Bouzari S**, Oloomi M, Fateh A, Vaziri F, Afrough P, Amanzadeh A, Siadat SD.

Microb Pathog. 2017 Dec;113:472-479. doi: 10.1016/j.micpath.2017.11.007. Epub 2017 Nov 11.

101 - Construction and evaluation of the immune protection of a recombinant divalent protein composed of the MrpA from MR/P fimbriae and flagellin of Proteus mirabilis strain against urinary tract infection.

Habibi M, Asadi Karam MR, **Bouzari S.**

Microb Pathog. 2018 Feb 13. pii: S0882-4010(18)30101-3. doi: 10.1016/j.micpath.2018.02.023. [Epub ahead of print]

102- Antiadhesive hydroalcoholic extract from Apium graveolens fruits prevents bladder and kidney infection against uropathogenic E. coli.

Sarshar S, Sendker J, Qin X, Goycoolea FM, Asadi Karam MR, Habibi M, **Bouzari S**, Dobrindt U, Hensel A.

Fitoterapia. 2018 Feb 26. pii: S0367-326X(18)30036-4. doi: 10.1016/j.fitote.2018.02.029. [Epub ahead of print]

103- A novel multi-peptide subunit vaccine admixed with AddaVax adjuvant produces significant immunogenicity and protection against *Proteus mirabilis* urinary tract infection in mice model.

Choubini E, Habibi M, Khorshidi A, Ghasemi A, Asadi Karam MR, **Bouzari S**.

Mol Immunol. 2018 Apr; 96:88-97. doi: 10.1016/j.molimm.2018.03.001. Epub 2018 Mar 9.

104- *In silico* Design, and *In vitro* Expression of a Fusion Protein Encoding *Brucella abortus* L7/L12 and SOmp2b Antigens.

Golshani M, Ghasemian M, Gheibi N, **Bouzari S**.

Adv Biomed Res. 2018 Feb 16;7:21. doi: 10.4103/abr.abr_10_17. eCollection 2018.

105- A heterologous prime-boost route of vaccination based on the truncated MrpH adhesin and adjuvant properties of the flagellin from *Proteus mirabilis* against urinary tract infections.

Asadi Karam MR, Shirzad AM, Habibi M, **Bouzari S**.

Int Immunopharmacol. 2018 May;58:40-47. doi: 10.1016/j.intimp.2018.03.009. Epub 2018 Mar 14.

106- Distribution of extended-spectrum β -lactam, quinolone and carbapenem resistance genes, and genetic diversity among uropathogenic *Escherichia coli* isolates in Tehran, Iran.

Shahbazi S, Asadi Karam MR, Habibi M, Talebi A, **Bouzari S**.

J Glob Antimicrob Resist. 2018 Mar 23;14:118-125. doi: 10.1016/j.jgar.2018.03.006. [Epub ahead of print]

107- Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma.

Oloomi M, Moazzezy N, **Bouzari S**.

Biomed Res Int. 2018 Feb 12;2018:7154708. doi: 10.1155/2018/7154708. eCollection 2018.

108- Characterization of killed but metabolically active uropathogenic *Escherichia coli* strain as possible vaccine candidate for urinary tract infection.

Jalili Z, Saleh M, **Bouzari S**, Pooya M.

Microb Pathog. 2018 Jun 20;122:184-190. doi: 10.1016/j.micpath.2018.06.027. [Epub ahead of print]

109- A-NGR fusion protein induces apoptosis in human cancer cells.

Mohammadi-Farsani A, Habibi-Roudkenar M, Golkar M, Shokrgozar MA, Jahanian-Najafabadi A, KhanAhmad H, Valiyari S, **Bouzari S**.

EXCLI J. 2018 Jun 25;17:590-597. doi: 10.17179/excli2018-1120. eCollection 2018.

110- Prevalence and antimicrobial resistance of shiga toxin-producing *Escherichia coli* and enteropathogenic *Escherichia coli* isolated from patients with acute diarrhea.

Bouzari S, Farhang E, Hosseini SM, Alikhani MY.

Iran J Microbiol. 2018 Jun;10(3):151-157.

111- Anti-tumor activity of *Escherichia coli* Shiga toxin A subunit delivered by SF9 insect cells.

Oloomi M, Imani M, Behzadi R, Asori M, **Bouzari S**, Mokhlesi B.

J Pharmacol Sci. 2018 Sep;138(1):71-75. doi: 10.1016/j.jphs.2018.09.003. Epub 2018 Sep 22.

112- Comparison of the protective immunity elicited by a Brucella cocktail protein vaccine (rL7/L12+rTOmp31+rSOmp2b) in two different adjuvant formulations in BALB/c mice.

Golshani M, Amani M, Siadat SD, Nejati-Moheimani M, Arsang A, **Bouzari S**.

Mol Immunol. 2018 Nov;103:306-311. doi: 10.1016/j.molimm.2018.10.002. Epub 2018 Oct 18.

113- Relationships between Virulence Factors and Antimicrobial Resistance among *Escherichia coli* Isolated from Urinary Tract Infections and Commensal Isolates in Tehran, Iran.

Karam MRA, Habibi M, **Bouzari S**.

Osong Public Health Res Perspect. 2018 Oct;9(5):217-224. doi: 10.24171/j.phrp.2018.9.5.02.

114- Effect of nontypeable Haemophilus influenzae protein E (PE) as a microbial adjuvant on the amount of antibody against PRP of Haemophilus influenzae type b (Hib) in BALB/c mice.

Tavakoli M, **Bouzari S**, Jafari A, Oloomi M, Asadi Karam MR, Najar-Peerayeh S, Siadat SD.

Microb Pathog. 2019 Apr;129:78-81. doi: 10.1016/j.micpath.2019.01.023. Epub 2019 Jan 22. No abstract available.

115- Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli.

Asadi Karam MR, Habibi M, **Bouzari S.**

Mol Immunol. 2019 Apr;108:56-67. doi: 10.1016/j.molimm.2019.02.007. Epub 2019 Feb 18. Review.

116- Antibiotic resistance, virulence and genetic diversity of Klebsiella pneumoniae in community- and hospital-acquired urinary tract infections in Iran.

Eghbalpoor F, Habibi M, Azizi O, Asadi Karam MR, **Bouzari S.**

Acta Microbiol Immunol Hung. 2019 Feb 26:1-18. doi: 10.1556/030.66.2019.006. [Epub ahead of print]

117- Development of an indirect ELISA based on whole cell Brucella abortus S99 lysates for detection of IgM anti-Brucella antibodies in human serum.

Tabasi M, Eybpoosh S, **Bouzari S.**

Comp Immunol Microbiol Infect Dis. 2019 Apr;63:87-93. doi: 10.1016/j.cimid.2019.01.007. Epub 2019 Jan 19.

118- Evaluation of immunogenicity of novel multi-epitope subunit vaccines in combination with poly I:C against Brucella melitensis and Brucella abortus infection.

Sadeghi Z, Fasihi-Ramandi M, **Bouzari S.**

Int Immunopharmacol. 2019 Oct;75:105829. doi: 10.1016/j.intimp.2019.105829. Epub 2019 Aug 19.

119- Comparative Study of Blood, Tissue and Serum Levels of Carcinoembryonic Antigen (CEA) Detection in Breast Cancer.

Moazzezy N, **Bouzari S,** Oloomi M.

Asian Pac J Cancer Prev. 2019 Oct 1;20(10):2979-2985. doi: 10.31557/APJCP.2019.20.10.2979.

120- Socio-demographic Characteristics, Biochemical and Cytokine Levels in Bulimia Nervosa Candidates for Sleeve Gastrectomy.

Tabasi M, Anbara T, Siadat SD, Kheirvari Khezerloo J, Elyasinia F, Bayanolhagh S, Sadat Safavi SA, Yazdannasab MR, Soroush A, **Bouzari S.**

Arch Iran Med. 2020 Jan 1;23(1):23-30.

121- Characterization of Antibiotic-Susceptibility Patterns, Virulence Factor Profiles and Clonal Relatedness in *Proteus mirabilis* Isolates from Patients with Urinary Tract Infection in Iran.

Mirzaei A, Habibi M, **Bouzari S**, Asadi Karam MR.

Infect Drug Resist. 2019 Dec 27;12:3967-3979. doi: 10.2147/IDR.S230303. eCollection 2019.

122- Surface display of uropathogenic *Escherichia coli* FimH in *Lactococcus lactis*: In vitro characterization of recombinant bacteria and its protectivity in animal model.

Derakhshandeh S, Shahrokhi N, Khalaj V, Habibi M, Moazzezy N, Asadi Karam MR, **Bouzari S**.

Microb Pathog. 2020 Apr;141:103974. doi: 10.1016/j.micpath.2020.103974. Epub 2020 Jan 8.

123- Mannosylated chitosan nanoparticles loaded with FliC antigen as a novel vaccine candidate against *Brucella melitensis* and *Brucella abortus* infection.

Sadeghi Z, Fasihi-Ramandi M, Azizi M, **Bouzari S**.

J Biotechnol. 2020 Feb 20;310:89-96. doi: 10.1016/j.jbiotec.2020.01.016. Epub 2020 Feb 1.

124- First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against *Pseudomonas aeruginosa* Isolated from Patients with Urinary Tract Infection in Tehran, Iran.

Rahimzadeh M, Habibi M, **Bouzari S**, Asadi Karam MR.

Infect Drug Resist. 2020 Feb 17;13:533-541. doi: 10.2147/IDR.S243301. eCollection 2020.

125- The relationship between phylogenetic groups and antibiotic susceptibility patterns of *Escherichia coli* strains isolated from feces and urine of patients with acute or recurrent urinary tract infection.

Norouzian H, Katouli M, Shahrokhi N, Sabeti S, Pooya M, **Bouzari S**.

Iran J Microbiol. 2019 Dec;11(6):478-487.

126- Comparing blood versus tissue-based biomarkers expression in breast cancer patients.

Oloomi M, Moazzezy N, **Bouzari S**.

Heliyon. 2020 Apr 3;6(4):e03728. doi: 10.1016/j.heliyon.2020.e03728. eCollection 2020 Apr.

126- Novel fusion protein NGR-sIL-24 for targetedly suppressing cancer cell growth via apoptosis.

Valiyari S, Salimi M, **Bouzari S**.

Cell Biol Toxicol. 2020 Apr;36(2):179-193. doi: 10.1007/s10565-020-09519-3. Epub 2020 Apr 1.

127- Evaluation of Poly(I:C) and combination of CpG ODN plus Montanide ISA adjuvants to enhance the efficacy of outer membrane vesicles as an acellular vaccine against *Brucella melitensis* infection in mice.

Golshani M, Amani M, Amirzadeh F, Nazeri E, Davar Siadat S, Nejati-Moheimani M, Arsang A, **Bouzari S**.

Int Immunopharmacol. 2020 Jul;84:106573. doi: 10.1016/j.intimp.2020.106573. Epub 2020 May 23

128- Main gut bacterial composition differs between patients with type 1 and type 2 diabetes and non-diabetic adults.

Ejtahed HS, Hoseini-Tavassol Z, Khatami S, Zangeneh M, Behrouzi A, Ahmadi Badi S, Moshiri A, Hasani-Ranjbar S, Soroush AR, Vaziri F, Fateh A, Ghanei M, **Bouzari S**, Najari-Peerayeh S, Siadat SD, Larijani B.

J Diabetes Metab Disord. 2020 Feb 8;19(1):265-271. doi: 10.1007/s40200-020-00502-7. eCollection 2020 Jun.

129- Nanoparticle-Based Vaccines for Brucellosis: Calcium Phosphate Nanoparticles-Adsorbed Antigens Induce Cross Protective Response in Mice.

Sadeghi Z, Fasihi-Ramandi M, **Bouzari S**.

Int J Nanomedicine. 2020 May 29;15:3877-3886. doi: 10.2147/IJN.S249942. eCollection 2020.